Masahiro Tsuboi

30.9k total citations · 9 hit papers
377 papers, 13.7k citations indexed

About

Masahiro Tsuboi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Masahiro Tsuboi has authored 377 papers receiving a total of 13.7k indexed citations (citations by other indexed papers that have themselves been cited), including 264 papers in Pulmonary and Respiratory Medicine, 161 papers in Oncology and 63 papers in Surgery. Recurrent topics in Masahiro Tsuboi's work include Lung Cancer Diagnosis and Treatment (175 papers), Lung Cancer Treatments and Mutations (174 papers) and Lung Cancer Research Studies (71 papers). Masahiro Tsuboi is often cited by papers focused on Lung Cancer Diagnosis and Treatment (175 papers), Lung Cancer Treatments and Mutations (174 papers) and Lung Cancer Research Studies (71 papers). Masahiro Tsuboi collaborates with scholars based in Japan, United States and United Kingdom. Masahiro Tsuboi's co-authors include Harubumi Kato, Tetsuya Mitsudomi, Hisao Asamura, Hirohito Tada, Keiju Aokage, Hisashi Saji, Kenji Suzuki, Norihiko Ikeda, Genichiro Ishii and Shinichiro Nakamura and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Masahiro Tsuboi

354 papers receiving 13.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial

2022 764 citations Hisashi Saji, Morihito Okada et al. profile →
A Randomized Trial of Adjuvant Chemotherapy with Uracil–Tegafur for Adenocarcinoma of the Lung

2004 625 citations Harubumi Kato, Yukito Ichinose et al. profile →
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the T Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer

2007 482 citations Masahiro Tsuboi et al. profile →
A Prospective Radiological Study of Thin-Section Computed Tomography to Predict Pathological Noninvasiveness in Peripheral Clinical IA Lung Cancer (Japan Clinical Oncology Group 0201)

2011 464 citations Kanji Nagai, Masahiro Tsuboi et al. profile →
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer

2023 460 citations Heather A. Wakelee, Moïshe Liberman et al. profile →
A Phase III Randomized Trial of Lobectomy Versus Limited Resection for Small-sized Peripheral Non-small Cell Lung Cancer (JCOG0802/WJOG4607L)

2009 400 citations Hisashi Saji, Shinichiro Nakamura et al. Japanese Journal of Clinical Oncology profile →
Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial

2019 310 citations Hisashi Saji, Keiju Aokage et al. Journal of Thoracic and Cardiovascular Surgery profile →
Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC

2023 263 citations Masahiro Tsuboi, Terufumi Kato et al. profile →
A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer

2020 198 citations Shun‐ichi Watanabe, Masashi Wakabayashi et al. Journal of Thoracic and Cardiovascular Surgery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Masahiro Tsuboi Japan	56	10.6k	5.3k	2.5k	1.7k	1.5k	377	13.7k
Brian D. Kavanagh United States	55	7.6k 0.7×	3.7k 0.7×	4.1k 1.6×	2.5k 1.5×	846 0.6×	297	13.1k
Mizuki Nishino United States	56	6.1k 0.6×	5.5k 1.0×	1.7k 0.7×	1.0k 0.6×	1.4k 0.9×	228	10.9k
Mitchell Machtay United States	56	7.9k 0.7×	4.1k 0.8×	2.8k 1.1×	4.4k 2.6×	1.2k 0.8×	299	14.3k
Vincent Khoo United Kingdom	47	7.2k 0.7×	2.6k 0.5×	3.0k 1.2×	2.4k 1.4×	2.0k 1.3×	227	11.4k
Joe Y. Chang United States	65	9.9k 0.9×	3.9k 0.7×	4.5k 1.8×	1.8k 1.1×	917 0.6×	353	14.0k
Anne‐Marie C. Dingemans Netherlands	54	5.7k 0.5×	4.9k 0.9×	1.9k 0.7×	796 0.5×	1.8k 1.2×	368	10.2k
Peter Goldstraw United Kingdom	50	11.6k 1.1×	5.3k 1.0×	2.4k 0.9×	2.6k 1.5×	1.3k 0.8×	169	14.8k
Hisao Asamura Japan	72	13.3k 1.3×	5.4k 1.0×	3.4k 1.3×	2.5k 1.5×	1.7k 1.1×	314	18.1k
Lorenzo Spaggiari Italy	49	6.3k 0.6×	2.9k 0.6×	1.4k 0.5×	2.0k 1.2×	1.6k 1.1×	507	10.4k
Hak Choy United States	50	6.8k 0.6×	3.9k 0.7×	2.1k 0.8×	1.0k 0.6×	1.1k 0.7×	182	9.6k

Countries citing papers authored by Masahiro Tsuboi

Since Specialization

Citations

This map shows the geographic impact of Masahiro Tsuboi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masahiro Tsuboi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masahiro Tsuboi more than expected).

Fields of papers citing papers by Masahiro Tsuboi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masahiro Tsuboi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masahiro Tsuboi. The network helps show where Masahiro Tsuboi may publish in the future.

Co-authorship network of co-authors of Masahiro Tsuboi

This figure shows the co-authorship network connecting the top 25 collaborators of Masahiro Tsuboi. A scholar is included among the top collaborators of Masahiro Tsuboi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masahiro Tsuboi. Masahiro Tsuboi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tsuboi, Masahiro, Li Zhou, Cheng He, et al.. (2024). Potential of circulating micrornas as biomarkers in perioperative management of lung cancer. 5. 100258–100258. 1 indexed citations

Taki, Tetsuro, Naoya Sakamoto, Shingo Sakashita, et al.. (2024). NETosis in pulmonary pleomorphic carcinoma. Cancer Science. 116(2). 524–532.

Garassino, Marina Chiara, Heather A. Wakelee, Jonathan Spicer, et al.. (2024). Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8012–8012. 2 indexed citations

Nomura, Kotaro, Keiju Aokage, Tokiko Nakai, et al.. (2024). EGFR mutation impacts recurrence in high-risk early-stage lung adenocarcinoma in the IASLC grading system. International Journal of Clinical Oncology. 29(3). 248–257. 2 indexed citations

Aokage, Keiju, Shohei Koyama, Shogo Kumagai, et al.. (2024). Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1–Positive NSCLC: A Phase II Trial (EAST ENERGY). Clinical Cancer Research. 30(24). 5584–5592. 4 indexed citations

Wakelee, Heather A., Moïshe Liberman, Terufumi Kato, et al.. (2023). KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.. Journal of Clinical Oncology. 41(17_suppl). LBA100–LBA100. 11 indexed citations

Kitagawa, Shingo, Yoshitaka Zenke, Kiyotaka Yoh, et al.. (2023). 236TiP Large-scale prospective observational study to develop a liquid-based detection system of minimal residual disease (MRD): LC-SCRUM-MRD. Annals of Oncology. 34. S275–S276. 1 indexed citations

Zenke, Yoshitaka, Kiyotaka Yoh, Shingo Kitagawa, et al.. (2023). 1282P Concordance of PD-L1 expression between biopsy and matched surgical specimen in early-stage non-small cell lung cancer: LC-SCRUM-Advantage/MRD. Annals of Oncology. 34. S740–S741. 1 indexed citations

Miyoshi, Tomohiro, et al.. (2023). Predictors of residual simultaneous multiple ground-glass nodule progression after dominant lesion resection. General Thoracic and Cardiovascular Surgery. 72(3). 183–191. 1 indexed citations

10.

Yoh, Kiyotaka, Yoshitaka Zenke, Shingo Kitagawa, et al.. (2023). 1276P Genomic screening by multi-gene assay for perioperative targeted therapy in patients with early-stage non-small cell lung cancer: LC-SCRUM-Advantage/MRD. Annals of Oncology. 34. S737–S737. 1 indexed citations

11.

Yoshino, Ichiro, Yasumitsu Moriya, Kenji Suzuki, et al.. (2023). Long-term outcome of patients with peripheral ground-glass opacity–dominant lung cancer after sublobar resections. Journal of Thoracic and Cardiovascular Surgery. 166(4). 1222–1231.e1. 12 indexed citations

12.

Sugimoto, Akira, Shigeki Umemura, Tomohiro Miyoshi, et al.. (2021). High proportion of tumor necrosis predicts poor survival in surgically resected high-grade neuroendocrine carcinoma of the lung. Lung Cancer. 157. 1–8. 3 indexed citations

13.

Hattori, Aritoshi, Kazuya Takamochi, Satoshi Shiono, et al.. (2021). Multicentre prospective observational study for pulmonary vein stump thrombus after anatomical lung resections. European Journal of Cardio-Thoracic Surgery. 61(1). 92–99. 15 indexed citations

14.

Sakai, Takashi, Keiju Aokage, Shinya Katsumata, et al.. (2021). Continuation of aspirin perioperatively for lung resection: a propensity matched analysis. Surgery Today. 51(6). 1054–1060.

15.

Ozaki, Masahiko, et al.. (2020). A Survey of Certified Review Boards under the Clinical Trials Act. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 51(5). 255–265. 1 indexed citations

16.

Suzuki, Jun, Toshiaki Yoshikawa, Tetsuya Nakatsura, et al.. (2020). Tumor-Infiltrating T Cells Concurrently Overexpress CD200R with Immune Checkpoints PD-1, CTLA-4, and TIM-3 in Non-Small-Cell Lung Cancer. Pathobiology. 88(3). 218–227. 7 indexed citations

17.

Makinoshima, Hideki, Shigeki Umemura, Ayako Suzuki, et al.. (2018). Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma. Cancer Research. 78(9). 2179–2190. 33 indexed citations

18.

Miyoshi, Tomohiro, Shigeki Umemura, Yuki Matsumura, et al.. (2016). Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung. Clinical Cancer Research. 23(3). 757–765. 139 indexed citations

19.

Yoshida, Junji, Genichiro Ishii, Tomoyuki Hishida, et al.. (2015). Limited resection trial for pulmonary ground-glass opacity nodules: case selection based on high-resolution computed tomography--interim results. Japanese Journal of Clinical Oncology. 45(7). 677–681. 25 indexed citations

20.

Kudoh, Shoji, Harubumi Kato, Yutaka Nishiwaki, et al.. (2008). Interstitial Lung Disease in Japanese Patients with Lung Cancer. American Journal of Respiratory and Critical Care Medicine. 177(12). 1348–1357. 365 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact